US20090081783A1 - Method for producing langerhans cells or interstitial dendritic cells or both from CD14+ monocytes - Google Patents
Method for producing langerhans cells or interstitial dendritic cells or both from CD14+ monocytes Download PDFInfo
- Publication number
- US20090081783A1 US20090081783A1 US11/897,617 US89761707A US2009081783A1 US 20090081783 A1 US20090081783 A1 US 20090081783A1 US 89761707 A US89761707 A US 89761707A US 2009081783 A1 US2009081783 A1 US 2009081783A1
- Authority
- US
- United States
- Prior art keywords
- cells
- monocytes
- model
- cell
- epithelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001616 monocyte Anatomy 0.000 title claims abstract description 154
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 title claims abstract description 64
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 title claims abstract description 64
- 210000001821 langerhans cell Anatomy 0.000 title claims abstract description 25
- 210000003535 interstitial dendritic cell Anatomy 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 178
- 238000000034 method Methods 0.000 claims abstract description 79
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 53
- 210000002540 macrophage Anatomy 0.000 claims abstract description 53
- 230000004069 differentiation Effects 0.000 claims abstract description 45
- 238000013334 tissue model Methods 0.000 claims abstract description 45
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- 239000008280 blood Substances 0.000 claims abstract description 38
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 32
- 230000002093 peripheral effect Effects 0.000 claims abstract description 26
- 210000003491 skin Anatomy 0.000 claims description 77
- 102000004127 Cytokines Human genes 0.000 claims description 36
- 108090000695 Cytokines Proteins 0.000 claims description 36
- 210000002510 keratinocyte Anatomy 0.000 claims description 36
- 239000004480 active ingredient Substances 0.000 claims description 35
- 210000004207 dermis Anatomy 0.000 claims description 34
- 210000002950 fibroblast Anatomy 0.000 claims description 34
- 230000002500 effect on skin Effects 0.000 claims description 30
- 210000001136 chorion Anatomy 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 24
- 210000001519 tissue Anatomy 0.000 claims description 24
- 239000011159 matrix material Substances 0.000 claims description 21
- 210000002615 epidermis Anatomy 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 16
- 210000004877 mucosa Anatomy 0.000 claims description 16
- 238000009331 sowing Methods 0.000 claims description 15
- 210000004379 membrane Anatomy 0.000 claims description 13
- 235000008935 nutritious Nutrition 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 210000000981 epithelium Anatomy 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 12
- 210000002752 melanocyte Anatomy 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000011835 investigation Methods 0.000 claims description 11
- 210000000716 merkel cell Anatomy 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- -1 polytetrafluoroethylene Polymers 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 230000001988 toxicity Effects 0.000 claims description 7
- 231100000419 toxicity Toxicity 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- 230000001506 immunosuppresive effect Effects 0.000 claims description 6
- 238000011160 research Methods 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000010354 integration Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 210000004927 skin cell Anatomy 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 210000004082 barrier epithelial cell Anatomy 0.000 claims description 3
- 210000003595 dermal dendritic cell Anatomy 0.000 claims description 3
- 230000004890 epithelial barrier function Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 210000002570 interstitial cell Anatomy 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000002372 labelling Methods 0.000 description 22
- 230000008569 process Effects 0.000 description 19
- 239000002243 precursor Substances 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 9
- 230000000622 irritating effect Effects 0.000 description 9
- 230000001235 sensitizing effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000049320 CD36 Human genes 0.000 description 7
- 108010045374 CD36 Antigens Proteins 0.000 description 7
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 7
- 102100025136 Macrosialin Human genes 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 230000002009 allergenic effect Effects 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 230000002519 immonomodulatory effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 6
- 101800003838 Epidermal growth factor Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000004163 cytometry Methods 0.000 description 6
- 229940116977 epidermal growth factor Drugs 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 210000004296 naive t lymphocyte Anatomy 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 4
- 229940057594 isuprel Drugs 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229940035722 triiodothyronine Drugs 0.000 description 4
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 3
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 3
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 108010017158 CCR7 Receptors Proteins 0.000 description 2
- 102000004428 CCR7 Receptors Human genes 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229920006127 amorphous resin Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000024715 positive regulation of secretion Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
- C12N5/0698—Skin equivalents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/091—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells melanocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/097—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells oral mucosa cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/24—Genital tract cells, non-germinal cells from gonads
- C12N2502/243—Cells of the female genital tract, non-germinal ovarian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
- C12N2503/06—Screening or testing on artificial skin
Definitions
- This invention relates to a method for producing dendritic cells, such as Langerhans cells and/or interstitial dendritic cells and/or dermal dendritic cells, from CD14 + monocytes isolated from peripheral circulatory blood.
- This invention also relates to tissue models prepared with such cells, and the use of such tissue models for testing active ingredients and/or studying biological/biochemical phenomena involved in skin tissue.
- Dendritic cells are cells having antigens described as sentries of the immune system. Indeed, they have a quasi-ubiquitous localization, i.e., in the thymus, systemic circulation, secondary lymphoid organs and also peripheral tissues such as the skin and the mono-stratified or pluri-stratified mucosae. Although there are a very small number of them in the organism, the DCs are at the centre of the triggering of specific immune responses, by exerting a control on the specificity, the intensity and the nature of the immune response and are placed at the interface between innate and acquired immunity. In addition to their function for igniting the immune response, the DCs also play a role in inducing peripheral tolerance.
- the precursors of DCs stem from the differentiation of CD34 + haematopoietic progenitors just as many populations of the immune system and blood cells. They are conveyed via the blood at the skin and the mucosae in order to differentiate and reside there as immature DCs. This immature state is expressed by a characteristic phenotype and a strong functional capability of capturing antigens.
- Two types of peripheral DCs are described according to their in vivo localization:
- LCs and IDCs stemming from skin or human mucosae, especially when combined with epithelial cells or mesenchymatous cells of the fibroblast type, consists of integrating them into three-dimensional organotypical cultures such as:
- U.S. Pat. No. 6,130,482 describes the co-culture of keratinocytes and precursors of LC in an adequate nutritious medium in order to carry out differentiation of the precursors into LCs, notably with the purpose of integrating them into an epidermis model in order to assess the synthesizing irritating or allergenic potency of a product.
- this patent describes the use of CD34 + haematopoietic progenitors stemming from umbilical cord blood with reference to the method described by Caux et al., Nature, 1992 Nov. 19, 360(6401):258-61, which comprises the growing of CD34 + haematopoietic progenitors in the presence of exogenous cytokines.
- 6,130,482 generally defines the precursors of LCs as being able to express CD1a + , but only the use of CD34 + haematopoietic cells as CD34 + precursors of LCs is described therein.
- the CD34 + haematopoietic cells are not very numerous in the peripheral blood and do not allow development of an industrially satisfactory differentiation method. Further, the use of precursors stemming from umbilical cord blood is unsatisfactory as this blood is not available in a large amount.
- French patent 2 833 271 B1 describes the differentiation of CD14 + monocytes in order to obtain LCs, IDCs, some LCs and some DCIs simultaneously, which may then be grown in the presence of epithelial cells and/or mesenchymatous cells stemming from skin or human mucosae.
- the following tissue models are described in this patent:
- Patent FR 2 833 271 B1 describes the differentiation of monocytes into LCs and/or into IDCs with the purpose of providing LCs and/or IDCs for developing immunocompetent tissue models close to normal human skin. Unexpectedly, it has now been found that this method may be further improved by using a simple, not very costly, and fast differentiation method.
- the present invention allows for generating LCs, or IDCs or LCs and IDCs simultaneously, or IDCs and macrophages and endothelial cells simultaneously or LCs and IDCs and macrophages and endothelial cells simultaneously, from a unique living precursor which stems from peripheral circulatory blood.
- the present invention further provides epidermis, epithelium, dermis, chorion, skin or mucosa models containing the aforementioned cells (LC, IDC/DCC, etc.), said models being of the best possible quality in order to reproduce an epidermis, an epithelium, a dermis, a chorion, a skin or a mucosa of a living being, preferably of a mammal, and more preferably of a human being.
- a further object of the present invention is to provide epithelial and/or conjunctive sheets as well as immunocompetent equivalents of skin or of mucosae.
- the present invention further provides a method for differentiating monocytes stemming from peripheral circulatory blood in order to obtain the aforementioned cells (LC, IDC/DCC, etc.)
- the present invention also provides skin models which may be utilized as an alternative method to animal experimentation, particularly for testing the irritating and/or sensitizing potency of a cosmetic ingredient.
- Another object of the present invention is to provide tissue models as described above for testing cosmetic, pharmaceutical or dermo-pharmoceutical active ingredients, and particularly for assessing any or all of their activity, toxicity or pharmacotoxicity.
- Yet another object of the present invention is to provide tissue models as described above for testing molecules or chemicals, and is especially useful for assessing their toxicity.
- An additional object of the present invention is to provide tissue models as described above which are useful for investigating biological/biochemical phenomena at intercellular and intracellular level.
- a still further object of the invention is to provide a tissue model which may be utilized as a research tool for pharmacotoxicological investigation, for example to conduct tests in vitro for predicting the allergizing/irritating/sensitizing power of external agents.
- Another object of the present invention is to provide a tissue model which may be utilized as a research tool for investigating substances having immunomodulating properties.
- the invention also relates to the use of the models as described above in tissue or cell engineering, particularly for repairing at least one portion of the tissues of a living being.
- peripheral circulatory blood means the blood of any living being having a blood system in which the blood accomplishes a circuit, notably at the periphery, preferably in mammals, and more preferably in a human being.
- active ingredient includes any substance, product or composition capable or potentially capable of providing a positive benefit to a product in either the agro-feeding, food, dermo-pharmaceutical, pharmaceutical, or cosmetics industry.
- a substance, product or composition capable or potentially capable of inhibiting an enzyme known to reduce collagen elastisity would be potentially capable of providing a positive benefit to an anti-aging cosmetic product and would thus be considered an active ingredient for the cosmetics industry.
- addition of exogenous cytokine means the addition of at least one cytokine in addition to the cytokines synthesized by the cells present in the relevant cell medium.
- the invention therefore relates to differentiation of CD14 + monocytes, in the presence of epithelial cells and/or mesenchymatous cells, including mesenchymatous cells of the fibroblast type, into:
- the present invention relates to differentiation of CD14 + monocytes into LCs and/or IDCs (without prior growing of the monocytes under conditions promoting their differentiation, and without prior growing with exogenous cytokines) in the presence of epithelial cells and/or mesenchymatous cells, for example of the fibroblast type, in order to obtain a cell model comprising LCs and/or IDCs, their culture being preferably performed essentially without significant addition of exogenous cytokines, meaning without adding any cytokine in addition to the endogenous cytokines synthesized by the cells present in the medium.
- the invention notably relates to a method for differentiating CD14 + monocytes into LCs and/or IDCs, comprising the following steps:
- CD14 + monocytes from circulatory blood, preferably the circulatory blood of a human being or other mal;
- the collected CD14 + monocytes into contact in a cell environment comprising epithelial cells and/or mesenchymatous under conditions which do not promote differentiation of the CD14 + monocytes into LCs, or IDCs, or LCs and IDCs.
- the epithelial cells are keratinocytes and the mesenchymatous cells are fibroblasts.
- the above step for maintaining CD14 + monocytes under conditions which do not promote their differentiation into DCs is preferably limited in time to the time needed in order to carry out sowing of the CD14 + monocytes shortly or even directly after they have been collected from the circulatory blood.
- conditions which do not promote differentiation of CD14 + monocytes into DCs may be obtained through a culture which does not comprise any exogenous cytokine.
- the purpose of the culture conditions is that the CD14 + monocytes do not engage in DC differentiation paths, and thus may utilize other culture conditions known in the art which may limit or prevent such differentiation.
- the present invention it is possible to obtain a gain in the number of precursors/cells as the present invention avoids the need to grow the CD14 + monocytes prior to differentiation, a step which is accompanied by a certain level of cell mortality.
- DCs generated in vitro are very sensitive and fragile cells.
- the first parameter to be checked is the yield in the obtained cells. It is obvious, but not quantifiable, that the loss and/or cell mortality of DCs is significant when the latter are sown in any cell culture model.
- the quality of the generated cells may also be increased through the use of the present invention.
- In vitro generation of DCs from monocytes is related to a cell differentiation phase under the effect of immune soluble mediators which are cytokines. It has been described that DCs of the LC and DDC type derived from monocytes are not “synchronous” in their cell differentiation process (Bechetoille, et al., Journal of Leukocytes Biology ). In other words, the CD14 + monocytes which have initiated their differentiation generate LCs and DCCs which do not all have the same differentiation stage. This imperfection may be corrected by avoiding this differentiation step as is accomplished by the present invention.
- the monocytes grown in the present invention are influenced by the cell, cytokine and matrix environment of the cell reconstructions, which forms a more physiological environment for differentiation of DCs.
- DCs generated in vitro have the capability of “maturating” spontaneously, which is a major problem as mature DCs may no longer be activated and stimulated.
- the immature conditions of these cells in vitro may be controlled, the risk of spontaneous maturity in vitro may be dispensed with by directly using monocytes as precursors of LCs and DCCs.
- the advantageous use of cell or tissue culture models according to the present invention as a system for differentiation of CD14 + monocytes into DCs is more physiological as it better reproduces the natural conditions for differentiation of DCs in the skin and in the mucosae and immature DCs which are comparable to their homologs in vivo may thereby be obtained.
- DCs derived from CD34 + progenitors and then grown in a reconstructed chorion in the presence of exogenous cytokines has a more satisfactory immaturity condition, in terms of replication of the HIV virus, than its homologs grown in the presence of exogenous cytokines (Dumont, et al., AIDS Res. and Hum. Retroviruses 20: 383-397, 2004).
- the obtained DCs are very different from DCs obtained by the prior art methods described previously, including FR 2 833 271 B1.
- CD14 + monocytes as precursors of skin DCs is a more physiological process as compared with the process described earlier. Indeed, in vivo in the organism, blood monocytes colonize the skin, where the cell, cytokine and matrix environment controls their differentiation. Integration of DCs differentiated beforehand in the present culture models was an interesting alternative which presently is less satisfactory than directly using their precursors which are the CD14 + monocytes. This improvement of the system is immunohistologically expressed by a more homogenous cell distribution of LCs and DCCs in the three-dimensional culture models of the present invention.
- the present invention notably relates to a unique cell precursor which, when it is co-cultivated:
- the present invention relates to a method for preparing LCs, or IDCs, or LCs and IDCs, from CD14 + monocytes stemming from peripheral circulatory blood of a living being, preferably of a human being, comprising differentiation of CD14 + monocytes into LCs or into IDCs or into LCs and IDCs by putting CD14 + monocytes in presence with a cell environment comprising epithelial cells, such as keratinocytes, and/or mesenchymatous cells, such as dermal fibroblasts.
- differentiation of CD14 + monocytes enables one to obtain IDCs and macrophages and endothelial cells, or LCs, IDCs, macrophages and endothelial cells.
- the distribution of the cell population of LCs and IDCs is a function of the cell type which is jointly grown with monocytes.
- the use of keratinocytes promotes differentiation into LCs and the use of fibroblasts promotes differentiation into IDCs.
- the differentiation of the monocytes is carried out without significant addition of any exogenous cytokine.
- no exogenous cytokine is added.
- LCs do no, or only very slightly, express activation labels (CD80, CD86, CCR7) and maturation labels (CD83, DC-LAMP).
- immature LCs express CCR6 and “functional” means the LCs are provided with antigene internalization capacities (immature condition), cell migration capacities (immature and activated condition), and antigenic presentation capacities (mature condition).
- the culture of monocytes with a mesenchymatous cell environment promotes differentiation of the monocytes into immature and functional IDCs.
- a mesenchymatous cell environment such as an environment with dermal fibroblasts
- the culture of monocytes with a cell environment comprising epithelial cells, such keratinocytes, and mesenchymatous cells, such as dermal fibroblasts promotes differentiation of the monocytes into typical LCs and IDCs.
- epithelial cells such as keratinocytes
- mesenchymatous cells such as dermal fibroblasts
- the proportion of epithelial cells and/or mesenchymatous cells, relative to the CD14 + monocytes, used for the culture (for the differentiation) depends on the cell distribution between LCs and/or IDCs and epithelial cells and/or mesenchymatous cells, which one skilled in the art wishes to obtain and one skilled in the art would select the proportion accordingly.
- the invention according to a second aspect relates to a method for growing CD14 + monocytes, the growing method comprising the integration into a cell or tissue model of CD14 + monocytes stemming from peripheral circulatory blood of a living being, preferably of a mammal, and more preferably of a human being, said cell or tissue model comprising epithelial cells, preferably keratinocytes, or mesenchymatous cells, preferably dermal fibroblasts, or both epithelial cells and mesenchymatous cells, in order to obtain differentiation of CD14 + monocytes within the model into LCs, or IDCs, or into LCs and IDCs, by growing CD14 + monocytes in the presence of such epithelial cells or mesenchymatous cells or both.
- a cell or tissue model comprising epithelial cells, preferably keratinocytes, or mesenchymatous cells, preferably dermal fibroblasts, or both epithelial cells and mesenchymatous
- the growing of monocytes is carried out without adding any exogenous cytokine.
- the cell or tissue model is selected from the group consisting in an epidermis model, an epithelium model, a dermis model, a chorion model, a skin model or a model of a mucosa, in particular of a gingival or vaginal mucosa.
- the three-dimensional culture model comprises a dermal or chorion matrix support selected from the group consisting of:
- the tissue model used comprises said dermal or chorion support on which epithelial cells, preferably keratinocytes, have been deposited at the surface.
- the cell or tissue model comprises at least one additional cell type, for example nerve cells and/or endothelial cells and/or melanocytes and/or lymphocytes and/or adipous cells and/or cutaneous annexes, such as bristles, hairs, sebaceous glands.
- additional cell type for example nerve cells and/or endothelial cells and/or melanocytes and/or lymphocytes and/or adipous cells and/or cutaneous annexes, such as bristles, hairs, sebaceous glands.
- a portion of the CD14 + monocytes differentiates into endothelial cells and macrophages, in particular when they are put into a cell or tissue model comprising at least mesenchymatous cells.
- the method mainly comprises LCs, or IDCs, or a mixture of LCs and IDCs, or a mixture of LCs, IDCs, endothelial cells and macrophages, or a mixture of IDCs, endothelial cells and macrophages.
- the cell or tissue model comprises an epithelial portion on a conjunctive matrix and is characterized in that the majority of the population of LCs are localized in the epithelial portion, and in that the majority of the IDCs, the macrophages and the endothelial cells are localized in the conjunctive matrix.
- the invention according to a third aspect, relates to a cell model comprising at least one of said LC and/or IDC populations, and further optionally comprising a population of macrophages and/or endothelial cells, capable of being obtained according to a method as defined earlier.
- Said model is characterized in that the obtained DCs are different from those obtained according to the methods described earlier, the main differences being concerned with synchronization of the cell differentiation steps for LCs and IDCs.
- the invention according to the fourth aspect relates to a tissue model, comprising at least one of said LC and/or IDC populations, and further optionally comprising a population of macrophages and/or endothelial cells, capable of being obtained according to a method as defined earlier, said tissue model being selected from the group consisting of an epidermis model, an epithelium model, a dermis model, a chorion model, a skin model, or a model of a mucosa, in particular of a gingival or vaginal mucosa.
- the cell or tissue model described above is immunocompetent.
- the tissue model comprises an epithelial portion comprising epithelial cells, such as keratinocytes, and a conjunctive matrix comprising mesenchymatous cells, such as dermal or chorion fibroblasts, said model being characterized in that the LCs are essentially localized in the epithelial portion, and in that the present IDCs and macrophages and/or endothelial cells are essentially localized in the conjunctive matrix.
- epithelial cells such as keratinocytes
- mesenchymatous cells such as dermal or chorion fibroblasts
- Said model is characterized in that the obtained DCs are different from those obtained according methods described earlier, the main differences being concerned with the more homogenous cell distribution of LCs and DCCs in the present three-dimensional culture models.
- the invention according to a fifth aspect relates to frozen CD14 + monocytes, isolated from the peripheral circulatory blood of a living being, in particular of a human being.
- the invention according to sixth aspect, relates to the use of at least one cell or tissue model as defined earlier as an investigation model in the field of cosmetics, dermo-pharmacy or pharmacy, and/or for active ingredient selection.
- the invention according to a seventh aspect relates to the use of at least one cell or tissue model as defined earlier, for investigating phenomena occurring in the organism's defense/infection processes, and activity, in particular the immuno-stimulating or immunosuppressive activity, of an active ingredient or for assessing or for inducing immunomodulation (immunotolerance or immunoactivation) by said active ingredient, or for conducting in vitro tests for predicting the allergizing/irritating/sensitizing potency of external agents or for investigating toxicity of molecules or chemicals.
- the invention according to an eighth aspect relates to the use of at least one cell or tissue model as defined earlier, for investigating the physiopathology of epithelial barriers; irritation of the skin and mucosae; aggressions of a biological nature such as for example viruses, retroviruses, such as HIV, bacteria, fungi, micro-organisms, particle antigens; phototoxicity; photoprotection; the effect of active ingredients, in particular of cosmetic or pharmaceutical ingredients; the effect of finished products, in particular of cosmetic or pharmaceutical products: the effect of molecules or chemicals; the mechanisms for infection by a pathogenic agent.
- a biological nature such as for example viruses, retroviruses, such as HIV, bacteria, fungi, micro-organisms, particle antigens
- phototoxicity photoprotection
- the effect of active ingredients in particular of cosmetic or pharmaceutical ingredients
- the effect of finished products in particular of cosmetic or pharmaceutical products: the effect of molecules or chemicals
- the mechanisms for infection by a pathogenic agent for investigating the physiopathology of epithelial barriers; irritation of the skin
- this invention relates to investigating toxicity of active ingredients or other substances.
- this investigation is carried out by studying cell labels, for example those labels of DCs.
- the invention according to a ninth aspect relates to the use of at least one cell or tissue model as defined earlier, for investigating mechanisms involved in the phenomena of viral infection, replication and transmission of viruses, including retroviruses like HIV, or for investigating and developing alternative therapeutic methods, including the administration of vaccines or drugs.
- the invention according to a tenth aspect relates to the use of at least one cell or tissue model as defined earlier for detecting the presence of a pathogenic agent such as for example viruses, retroviruses, such as HIV, bacteria, fungi, micro-organisms, particle antigens.
- a pathogenic agent such as for example viruses, retroviruses, such as HIV, bacteria, fungi, micro-organisms, particle antigens.
- the invention according to an eleventh aspect relates to the use of at least one cell or tissue model as defined earlier, for a medical, biomedical, or cosmetic application, in particular for modulating the immune or tolerance response in vitro or in vivo, as a result of an environmental aggression, in particular of the physical type, such as UV irradiation, of the chemical type, such as irritating/allergizing/sensitizing agents, of the biological type, in particular with a preventive or curative therapeutic purpose.
- the invention according to a twelfth aspect relates to the use of at least one cell or tissue model as defined earlier, for cell or tissue engineering applications, for medical or biomedical applications, for example in anti-cancer cell therapy, for example by a DCs injection capable of stimulating the immune response; for example in cell therapy in the case of an auto-immune disease, for example by creating an immunotolerance stimulation, for example by producing anergic T cells; for example in gene therapy of diseases affecting the immunitary system; or for developing and making vaccines.
- the invention according to a thirteenth aspect relates to a method for making a tissue model comprising:
- the epithelial cells are for example isolated from at least one skin tissue.
- Sowing of the skin or mucosal cells may be carried out before sowing or after having sown CD14 + monocytes.
- sowing of CD14 + monocytes is carried out simultaneously with the sowing of skin or mucosal cells.
- the invention according to a fourteenth aspect relates to a method for making a reconstructed skin or a reconstructed mucosa comprising an epithelial portion comprising keratinocytes or epithelial mucosal cells, optionally in the presence of Merkel cells and/or melanocytes, and a conjunctive matrix comprising dermal or mucosal fibroblasts, said method comprising:
- the cells are cells of a human being.
- these methods for making tissue models do not comprise any addition of exogenous cytokine.
- each example has a general scope.
- the peripheral circulatory blood was harvested by sampling venous blood on one or more human donors, preferably in vacutainers or bags supplemented with usual anti-coagulant products such as lithium heparin.
- the monocytes are recovered by proceeding with any physical separation method well-known to one skilled in the art and notably by sedimentation or centrifugation and they are eluted as such for subsequent cultures.
- the monocytes obtained as described in Example 1, are suspended in a nutritious medium, for example RPMI medium, supplemented with serum and a cryoprotective agent, such as DMSO (dimethyl sulfoxide), and then frozen.
- a nutritious medium for example RPMI medium
- serum for example fetal calf serum
- a cryoprotective agent such as DMSO (dimethyl sulfoxide)
- Monocytes were obtained according to the process of Example 1 or 2.
- 1 to 2.10 6 human keratinocytes and 1 to 2.10 6 human monocytes are jointly grown in a nutritious medium, for example of the K-SFM type, in culture dishes, for example of the 6-well plate type.
- the joint culture is maintained for 6 days in a nutritious medium, for example of the K-SFM type, without adding any exogenous cytokine.
- the cells are then recovered by an enzymatic method well-known to one skilled in the art and notably by trypsination.
- 2.10 5 cells of the mixed cell suspension consisting of keratinocytes and monocytes are incubated with a monoclonal anti-Langerine antibody, and then analyzed in flux cytometry. We observe up to 40% of Langerine+ LCs.
- Monocytes were obtained according to the process of Example 1 or 2.
- 1 to 2.10 6 human fibroblasts and 1 to 2.10 6 human monocytes are jointly grown in a nutritious medium, for example of the FBM type, in culture dishes for example of the 6-well plate type.
- the joint culture is maintained for 6 days in a nutritious medium, for example of the FBM type, without adding any exogenous cytokine.
- the cells are then recovered by an enzymatic method well-known to one skilled in the art and notably by trypsination.
- 2.10 5 cells of the mixed cell suspension consisting of fibroblasts and monocytes are incubated with a monoclonal anti-DC-SIGN antibody, and then analyzed in flux cytometry. We observe up to 60% of DC-SIGN+ DCCs.
- the model is made according to the protocol described in Example 3 or 4.
- Retinol is then added into the culture medium at a final concentration of 0.05% for 3 days.
- the culture supernatants are then recovered and analyzed.
- retinol causes stimulation of secretion of pro-inflammatory cytokines.
- the immunoactivating (induction and/or increase of the expression of labeled molecules) or immunosuppressive profile (inhibition and/or suppression of the expression of labeled molecules) of the tested active ingredients may be established.
- Monocytes were obtained according to the process of Example 1 or 2.
- the monocytes integrated into the reconstructed epidermis model differentiated into DCs of the LC type as demonstrated by observation of the lectin, Langerine.
- Monocytes were obtained according to the process of Example 1 or 2.
- the model was made according to the protocol described in Example 8, by simultaneously sowing together 0.5 à 1.10 5 melanocytes and/or Merkel cells stemming from normal human skin with keratinocytes.
- Monocytes were obtained according to the process of Example 1 or 2.
- the monocytes integrated into the epithelium model of gingival and vaginal reconstructed mucosae differentiated into DCs or the LC type as demonstrated by observation of the lectin Langerine.
- This model is the association of a reconstructed dermis culture on which an additional culture of a reconstructed epidermis is performed.
- the reconstructed dermis model was made according to the following protocol:
- the reconstructed skin model was made according to the following protocol:
- Monocytes were obtained according to the process of Example 1 or 2.
- the model is made according to the following protocol:
- the monocytes integrated and then grown in our reconstructed dermis model are capable of simultaneously differentiating into DCs of the DDC type, into macrophages and endothelial cells.
- Monocytes were obtained according to the process of Example 1 or 2.
- the monocytes integrated and then grown in our reconstructed chorion model of the gingival and vaginal type are capable of simultaneously differentiating into DCs of the IDC type, into macrophages and endothelial cells.
- Monocytes were obtained according to the process of Example 1 or 2.
- the culture of the reconstructed skin model was performed according to Example 11.
- the monocytes grown with keratinocytes in our reconstructed skin model differentiate into DCs of the LC type.
- Monocytes were obtained according to the process of Example 1 or 2.
- Monocytes were obtained according to the process of Example 1 or 2.
- Monocytes were obtained according to the process of Example 1 or 2.
- the performed labelings showed the simultaneous presence of DCCs (DC-SIGN+ cells), macrophages (CD68 + cells) and endothelial cells (CD31 + and CD36 + cells).
- DCCs DC-SIGN+ cells
- macrophages CD68 + cells
- endothelial cells CD31 + and CD36 + cells.
- the model was made according to the protocol described in Example 17, by simultaneously sowing together 1 to 5.10 4 melanocytes and/or Merkel cells stemming from normal human skin with keratinocytes.
- Monocytes were obtained according to the process of Example 1 or 2.
- the performed labelings showed the simultaneous presence of IDCs (DC-SIGN+ cells), macrophages (CD68 + cells) and endothelial cells (CD31 + cells and CD36 + ).
- Monocytes were obtained according to the process of Example 1 or 2.
- the performed labelings showed the simultaneous presence of LCs (Langerine+ cells and Birbeck+ granules) in the epidermal compartment of the cultures, and of DCCs (DC-SIGN+ cells), macrophages (CD68 + cells) and endothelial cells (CD31 + and CD36 + cells) in the dermal compartment of the cultures.
- LCs Longangerine+ cells and Birbeck+ granules
- DC-SIGN+ cells DCCs
- macrophages CD68 + cells
- endothelial cells CD31 + and CD36 + cells
- Monocytes were obtained according to the process of Example 1 or 2.
- the model is made according to the following protocol:
- the performed labelings detect simultaneous presence of LCs (Langerine+ cells and Birbeck granules) in the epidermal compartment of the cultures, and of DCCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells) in the dermal compartment of the cultures.
- LCs Longangerine+ cells and Birbeck granules
- DC-SIGN+ cells DCCs
- macrophages CD68+ cells
- endothelial cells CD31+ and CD36+ cells
- Monocytes were obtained according to the process of Example 1 or 2.
- the performed labelings showed the simultaneous presence of LCs (Langerine+ cells and Birbeck+ granules) in the epithelial compartment, and the presence of IDCs (DC-SIGN+ cells), macrophages (CD68 + cells) and endothelial cells (CD31 + and CD36 + cells) in the conjunctive compartment of the cultures.
- LCs Longangerine+ cells and Birbeck+ granules
- IDCs DC-SIGN+ cells
- macrophages CD68 + cells
- endothelial cells CD31 + and CD36 + cells
- LCs or DCCs CPM (untreated) CPM (active) 125 500 500 250 800 1500 500 1000 10000 1000 1500 22500 2000 2300 39850 4000 2800 47250 6000 3000 52500 8000 3800 55000
- the LCs and/or DCCs strongly stimulated proliferation of T lymphocytes (between 5.10 4 and 7.10 4 cpm) as compared with the untreated LCs and/or DCCs which only induce weak proliferation of naive T lymphocytes (between 1.10 3 and 4.10 3 cpm).
Abstract
The present invention relates to a method for preparing Langerhans cells or interstitial dendritic cells, or both, from CD14+ monocytes stemming from the peripheral circulatory blood of a living being, wherein the method comprises differentiation of CD14+ monocytes into either Langerhans cells, interstitial dendritic cells, or into both types of cells by placing the CD14+ monocytes in the presence of a cell environment comprising epithelial cells and/or mesenchymatous cells.
The present invention also relates to cell or tissue models comprising such prepared Langerhans cells and/or interstitial dendritic cells, and optionally macrophages and endothelial cells, and to the uses of such cell or tissue models.
Description
- This application claims priority under 35 U.S.C. §119 of French patent application no. 0653657, filed Sep. 4, 2006, hereby expressly incorporated herein by reference.
- This invention relates to a method for producing dendritic cells, such as Langerhans cells and/or interstitial dendritic cells and/or dermal dendritic cells, from CD14+ monocytes isolated from peripheral circulatory blood. This invention also relates to tissue models prepared with such cells, and the use of such tissue models for testing active ingredients and/or studying biological/biochemical phenomena involved in skin tissue.
- Dendritic cells (also referred to herein as “DCs”) are cells having antigens described as sentries of the immune system. Indeed, they have a quasi-ubiquitous localization, i.e., in the thymus, systemic circulation, secondary lymphoid organs and also peripheral tissues such as the skin and the mono-stratified or pluri-stratified mucosae. Although there are a very small number of them in the organism, the DCs are at the centre of the triggering of specific immune responses, by exerting a control on the specificity, the intensity and the nature of the immune response and are placed at the interface between innate and acquired immunity. In addition to their function for igniting the immune response, the DCs also play a role in inducing peripheral tolerance.
- The precursors of DCs stem from the differentiation of CD34+ haematopoietic progenitors just as many populations of the immune system and blood cells. They are conveyed via the blood at the skin and the mucosae in order to differentiate and reside there as immature DCs. This immature state is expressed by a characteristic phenotype and a strong functional capability of capturing antigens. Two types of peripheral DCs are described according to their in vivo localization:
-
- The Langerhans cells (also referred to herein as “LCs”) are localized at the epithelia of the malpighian type (skin and mucosae) where they specifically express langerine which is a lectin of types C. Langerine is involved in the formation of an intracytoplasmic organite, Birbeck's granule which is the specific ultrastructural and reference label of the LCs. LCs also express characteristic labels such as CD Ia and HLA-DR.
- Interstitial DCs (referred to herein as “IDCs”) are located at the lamina of mucosae, for example at the dermis of the skin. Insterstital DCs which are located at the dermis also called dermal DCs (referred to herein as “DDCs”). Thus, in the description which follows this type of cell is generally referred to interstitial dendritic cells, or IDCs, independently of whether they are at the lamina of the mucosae or at the dermis of the skin.
- These cells share many similarities and common labels with the cell line of monocytes/macrophages. In the dermis of the skin, DCCs specifically express DC-SIGN but also characteristic labels such as HLA-DR, FXIIIa, MMR and CD1a. Following the capture of an antigen, the LCs and IDCs migrate towards the lymph nodes in order to present the antigenic information to the lymphocytes T. This migration which is correlated with activation of LCs and IDCs is expressed by phenotypical and functional changes. For example, the “activated” LCs and IDCs acquire the expression of CD80 and CD86 which are co-stimulation labels and acquire the expression of the CCR7 receptor which is absolutely necessary to skin migration of the cells. At the lymph nodes, the activated LCs and IDCs acquire a phenotype of “mature” or “interdigitated” DCs from their interaction with T lymphocytes. This mature condition is synonym with a characteristic phenotype such as for example the expression of CD83 and DC-LAMP and with a strong allostimulating capacity i.e. the capability of inducing proliferation of T lymphocytes. Because of their capability of migrating towards proximal nodes after having captured an exo-antigen, the LCs and IDCs are responsible for many skin pathologies such as contact allergies and have recently been described as the first targets of the human immunodeficiency virus (HIV).
- An interesting use of LCs and IDCs stemming from skin or human mucosae, especially when combined with epithelial cells or mesenchymatous cells of the fibroblast type, consists of integrating them into three-dimensional organotypical cultures such as:
-
- Models of “reconstructed epidermises” and of “reconstructed mucosae”, for example of the vaginal and oral type, exclusively integrating LCs (Régnier et al., JID 1997; 109:510-2; European Patent No. 0 789 074; Sivard et al., Exp. Dermatol. 2003; 12:346-55),
- Models of “reconstructed dermis” and of “reconstructed chorion”, integrating DDCs or IDCs (Guironnet et al., JID 2001; 116:933-9 and Dumont et al., AIDS Res. Hum. Retroviruses 2004; 20:383-97).
- Today, these uses are extremely limited because: (1) the absence of a fast, simplified and inexpensive industrial scale method for producing in vitro LCs and IDCs and, (2) of the imperfection of the described prior art 3D models which exclusively show the epithelial portion or the conjunctive portion of the reconstructed tissue and but not both of the associated tissue compartments.
- The articles of Régnier et al., Sivard et al. and Dumont et al. deal with the use of CD34+ precursors stemming from umbilical chord blood which has the following major drawbacks: (1) the number of isolated CD34+ progenitors is limited since they are extracted from umbilical chord blood which is a limited source, and are therefore difficult to use industrially; (2) the prior culture (requiring 6 to 12 days) of the CD34+ progenitors before their integration into the 3D models which is done in order to induce their differentiation into LCs or IDCs; and (3) the requirement of these described methods that exogenous cytokines be added to the media utilized for growing reconstructed epidermises, reconstructed mucosae and reconstructed chorions integrating the LCs or some IDCs.
- In the article of Guironnet et al., the authors have generated DCCs from blood monocytes in order to integrate them into a reconstructed dermis model. Similar to those limitations discussed above, two drawbacks of the Guironnet method need to be highlighted: (1) the prior culture of monocytes (for 6 days) before their integration into the reconstructed dermis that is required in order to induce their differentiation into DCCS; and (2) the addition of exogenous cytokines in the media for growing the reconstructed dermis integrating the DCCs. In this same article, the authors also show that monocytes directly integrated into the equivalent dermis and without adding any cytokines, do not differentiate into DCs.
- U.S. Pat. No. 6,130,482 describes the co-culture of keratinocytes and precursors of LC in an adequate nutritious medium in order to carry out differentiation of the precursors into LCs, notably with the purpose of integrating them into an epidermis model in order to assess the synthesizing irritating or allergenic potency of a product. However, this patent describes the use of CD34+ haematopoietic progenitors stemming from umbilical cord blood with reference to the method described by Caux et al., Nature, 1992 Nov. 19, 360(6401):258-61, which comprises the growing of CD34+ haematopoietic progenitors in the presence of exogenous cytokines. U.S. Pat. No. 6,130,482 generally defines the precursors of LCs as being able to express CD1a+ , but only the use of CD34+ haematopoietic cells as CD34+ precursors of LCs is described therein. The CD34+ haematopoietic cells are not very numerous in the peripheral blood and do not allow development of an industrially satisfactory differentiation method. Further, the use of precursors stemming from umbilical cord blood is unsatisfactory as this blood is not available in a large amount.
- More recently, French patent 2 833 271 B1 describes the differentiation of CD14+ monocytes in order to obtain LCs, IDCs, some LCs and some DCIs simultaneously, which may then be grown in the presence of epithelial cells and/or mesenchymatous cells stemming from skin or human mucosae. The following tissue models are described in this patent:
-
- Models of “reconstructed epidermis” and of “reconstructed mucosae” exclusively integrating LCs,
- Models of “reconstructed dermis” and of “reconstructed chorion” integrating DCCs or IDCs,
- Models of “reconstructed skins” and of “reconstructed mucosae” integrating LCs and IDCs simultaneously.
- As is the issue with the other prior art methods described above, a drawback of the method described in French patent 2883271 is the need for prior growing of monocytes (i.e., for 6 days) in the presence of exogenous cytokines before integrating them into 3D models, which is done in order to induce their differentiation into LCs, into IDCs, or into LCs and IDCs simultaneously.
- Of the above described methods, only the method of Patent FR 2 833 271 B1 describes the differentiation of monocytes into LCs and/or into IDCs with the purpose of providing LCs and/or IDCs for developing immunocompetent tissue models close to normal human skin. Unexpectedly, it has now been found that this method may be further improved by using a simple, not very costly, and fast differentiation method.
- Thus, none of the existing art provides all of the advantages and benefits of the present invention.
- With the invention, it is possible for the first time to solve each of the technical problems set forth earlier, in a safe, reliable, and reproducible way and in a manner which may be used on an industrial and commercial scale and preferably on an industrical scale in the agro-feeding, medical, pharmaceutical, or cosmetic industries.
- The present invention allows for generating LCs, or IDCs or LCs and IDCs simultaneously, or IDCs and macrophages and endothelial cells simultaneously or LCs and IDCs and macrophages and endothelial cells simultaneously, from a unique living precursor which stems from peripheral circulatory blood.
- The present invention further provides epidermis, epithelium, dermis, chorion, skin or mucosa models containing the aforementioned cells (LC, IDC/DCC, etc.), said models being of the best possible quality in order to reproduce an epidermis, an epithelium, a dermis, a chorion, a skin or a mucosa of a living being, preferably of a mammal, and more preferably of a human being. A further object of the present invention is to provide epithelial and/or conjunctive sheets as well as immunocompetent equivalents of skin or of mucosae.
- The present invention further provides a method for differentiating monocytes stemming from peripheral circulatory blood in order to obtain the aforementioned cells (LC, IDC/DCC, etc.)
- The present invention also provides skin models which may be utilized as an alternative method to animal experimentation, particularly for testing the irritating and/or sensitizing potency of a cosmetic ingredient.
- Another object of the present invention is to provide tissue models as described above for testing cosmetic, pharmaceutical or dermo-pharmoceutical active ingredients, and particularly for assessing any or all of their activity, toxicity or pharmacotoxicity.
- Yet another object of the present invention is to provide tissue models as described above for testing molecules or chemicals, and is especially useful for assessing their toxicity.
- An additional object of the present invention is to provide tissue models as described above which are useful for investigating biological/biochemical phenomena at intercellular and intracellular level.
- A still further object of the invention is to provide a tissue model which may be utilized as a research tool for pharmacotoxicological investigation, for example to conduct tests in vitro for predicting the allergizing/irritating/sensitizing power of external agents.
- Another object of the present invention is to provide a tissue model which may be utilized as a research tool for investigating substances having immunomodulating properties.
- The invention also relates to the use of the models as described above in tissue or cell engineering, particularly for repairing at least one portion of the tissues of a living being.
- These and other features, aspects, and advantages of the present invention will become evident to those skilled in the art from a reading of the present disclosure.
- All percentages and ratios used herein are by weight of the total composition, unless otherwise designated. All publications cited herein are incorporated by reference in their entirety.
- Within the scope of the invention, when discussing “cells”, this always refers to “living cells”, unless stated otherwise.
- As used herein, “peripheral circulatory blood”, means the blood of any living being having a blood system in which the blood accomplishes a circuit, notably at the periphery, preferably in mammals, and more preferably in a human being.
- As used herein, “active ingredient”, includes any substance, product or composition capable or potentially capable of providing a positive benefit to a product in either the agro-feeding, food, dermo-pharmaceutical, pharmaceutical, or cosmetics industry. For example, a substance, product or composition capable or potentially capable of inhibiting an enzyme known to reduce collagen elastisity would be potentially capable of providing a positive benefit to an anti-aging cosmetic product and would thus be considered an active ingredient for the cosmetics industry.
- As used herein, “addition of exogenous cytokine” means the addition of at least one cytokine in addition to the cytokines synthesized by the cells present in the relevant cell medium.
- The invention therefore relates to differentiation of CD14+ monocytes, in the presence of epithelial cells and/or mesenchymatous cells, including mesenchymatous cells of the fibroblast type, into:
- LCs,
- IDCs,
- LCs and IDCs simultaneously,
- IDCs and macrophages and/or endothelial cells simultaneously,
- LCs and IDCs and macrophages and/or endothelial cells simultaneously.
- The present invention relates to differentiation of CD14+ monocytes into LCs and/or IDCs (without prior growing of the monocytes under conditions promoting their differentiation, and without prior growing with exogenous cytokines) in the presence of epithelial cells and/or mesenchymatous cells, for example of the fibroblast type, in order to obtain a cell model comprising LCs and/or IDCs, their culture being preferably performed essentially without significant addition of exogenous cytokines, meaning without adding any cytokine in addition to the endogenous cytokines synthesized by the cells present in the medium.
- The invention notably relates to a method for differentiating CD14+ monocytes into LCs and/or IDCs, comprising the following steps:
- collecting CD14+ monocytes from circulatory blood, preferably the circulatory blood of a human being or other mamal;
- maintaining the collected CD14+ monocytes under conditions which do not promote their differentiation into DCs;
- placing the collected CD14+ monocytes into contact in a cell environment comprising epithelial cells and/or mesenchymatous under conditions which do not promote differentiation of the CD14+ monocytes into LCs, or IDCs, or LCs and IDCs. Preferably the epithelial cells are keratinocytes and the mesenchymatous cells are fibroblasts.
- The above step for maintaining CD14+ monocytes under conditions which do not promote their differentiation into DCs is preferably limited in time to the time needed in order to carry out sowing of the CD14+ monocytes shortly or even directly after they have been collected from the circulatory blood.
- Advantageously, conditions which do not promote differentiation of CD14+ monocytes into DCs may be obtained through a culture which does not comprise any exogenous cytokine. However, one skilled in the art will recognize that the purpose of the culture conditions is that the CD14+ monocytes do not engage in DC differentiation paths, and thus may utilize other culture conditions known in the art which may limit or prevent such differentiation.
- Through the use of the present invention, it is possible to obtain a gain in the number of precursors/cells as the present invention avoids the need to grow the CD14+ monocytes prior to differentiation, a step which is accompanied by a certain level of cell mortality.
- DCs generated in vitro are very sensitive and fragile cells. The first parameter to be checked is the yield in the obtained cells. It is obvious, but not quantifiable, that the loss and/or cell mortality of DCs is significant when the latter are sown in any cell culture model. The use of CD14+ monocytes according to the present invention, as precursors of DCs, remedies this problem and thus allows a better yield in cells.
- With the present invention, it is also possible to obtain a gain in time as the differentiation of monocytes into LCs or IDCs generally requires six days of culture.
- With the present invention it is further possible to obtain a gain in reagents as preferably no exogenous cytokine is used.
- The quality of the generated cells may also be increased through the use of the present invention. In vitro generation of DCs from monocytes is related to a cell differentiation phase under the effect of immune soluble mediators which are cytokines. It has been described that DCs of the LC and DDC type derived from monocytes are not “synchronous” in their cell differentiation process (Bechetoille, et al., Journal of Leukocytes Biology). In other words, the CD14+ monocytes which have initiated their differentiation generate LCs and DCCs which do not all have the same differentiation stage. This imperfection may be corrected by avoiding this differentiation step as is accomplished by the present invention. The monocytes grown in the present invention are influenced by the cell, cytokine and matrix environment of the cell reconstructions, which forms a more physiological environment for differentiation of DCs.
- It is well known that DCs generated in vitro have the capability of “maturating” spontaneously, which is a major problem as mature DCs may no longer be activated and stimulated. Although the immature conditions of these cells in vitro may be controlled, the risk of spontaneous maturity in vitro may be dispensed with by directly using monocytes as precursors of LCs and DCCs. Also, the advantageous use of cell or tissue culture models according to the present invention as a system for differentiation of CD14+ monocytes into DCs is more physiological as it better reproduces the natural conditions for differentiation of DCs in the skin and in the mucosae and immature DCs which are comparable to their homologs in vivo may thereby be obtained.
- In this same context, by using CD14+ monocytes as precursors of DCs, as opposed to the use of DCs generated beforehand, it is possible to generate in the present models for growing phenotypically more immature and functionally more sensitive LCs and DCCs. Indeed, and in this context, it has been described that DCs derived from CD34+ progenitors and then grown in a reconstructed chorion in the presence of exogenous cytokines has a more satisfactory immaturity condition, in terms of replication of the HIV virus, than its homologs grown in the presence of exogenous cytokines (Dumont, et al., AIDS Res. and Hum. Retroviruses 20: 383-397, 2004). The obtained DCs are very different from DCs obtained by the prior art methods described previously, including FR 2 833 271 B1.
- Further, direct use of CD14+ monocytes as precursors of skin DCs is a more physiological process as compared with the process described earlier. Indeed, in vivo in the organism, blood monocytes colonize the skin, where the cell, cytokine and matrix environment controls their differentiation. Integration of DCs differentiated beforehand in the present culture models was an interesting alternative which presently is less satisfactory than directly using their precursors which are the CD14+ monocytes. This improvement of the system is immunohistologically expressed by a more homogenous cell distribution of LCs and DCCs in the three-dimensional culture models of the present invention.
- Advantageously, with the present invention, it is possible to freeze freshly isolated monocytes before their use in the models.
- With the present invention, it is also possible to generate cells having substantially the same phenotype and the same functions as their in vivo homologs.
- The present invention notably relates to a unique cell precursor which, when it is co-cultivated:
-
- In an epithelial environment, differentiates phenotypically and/or functionally into LCs,
- In a conjunctive environment differentiates phenotypically and/or functionally into IDCs, macrophages and endothelial cells.
- Thus, the present invention according to a first aspect, relates to a method for preparing LCs, or IDCs, or LCs and IDCs, from CD14+ monocytes stemming from peripheral circulatory blood of a living being, preferably of a human being, comprising differentiation of CD14+ monocytes into LCs or into IDCs or into LCs and IDCs by putting CD14+ monocytes in presence with a cell environment comprising epithelial cells, such as keratinocytes, and/or mesenchymatous cells, such as dermal fibroblasts.
- Advantageously, differentiation of CD14+ monocytes enables one to obtain IDCs and macrophages and endothelial cells, or LCs, IDCs, macrophages and endothelial cells. Advantageously, the distribution of the cell population of LCs and IDCs is a function of the cell type which is jointly grown with monocytes. The use of keratinocytes promotes differentiation into LCs and the use of fibroblasts promotes differentiation into IDCs.
- Advantageously, the differentiation of the monocytes is carried out without significant addition of any exogenous cytokine. According to one particularly preferred embodiment, no exogenous cytokine is added.
- Advantageously, growing monocytes with an epithelial cell environment, such as keratinocytes, promotes differentiation of the monocytes into immature and functional LCs. As used herein, “immature” means that the LCs do no, or only very slightly, express activation labels (CD80, CD86, CCR7) and maturation labels (CD83, DC-LAMP). On the other hand, immature LCs express CCR6 and “functional” means the LCs are provided with antigene internalization capacities (immature condition), cell migration capacities (immature and activated condition), and antigenic presentation capacities (mature condition).
- According to one preferred embodiment, the culture of monocytes with a mesenchymatous cell environment, such as an environment with dermal fibroblasts, promotes differentiation of the monocytes into immature and functional IDCs. Reference is made to the definitions of “immature” and “functional” above, with the exception that immature IDCs do not express CCR6.
- Advantageously, the culture of monocytes with a cell environment comprising epithelial cells, such keratinocytes, and mesenchymatous cells, such as dermal fibroblasts, promotes differentiation of the monocytes into typical LCs and IDCs. As used herein, “typical” means close to their homologs in vivo in terms of immature phenotype and functionality, i.e., of their capabilities of reacting after stimulation, stress, etc.
- The proportion of epithelial cells and/or mesenchymatous cells, relative to the CD14+ monocytes, used for the culture (for the differentiation) depends on the cell distribution between LCs and/or IDCs and epithelial cells and/or mesenchymatous cells, which one skilled in the art wishes to obtain and one skilled in the art would select the proportion accordingly.
- The invention according to a second aspect relates to a method for growing CD14+ monocytes, the growing method comprising the integration into a cell or tissue model of CD14+ monocytes stemming from peripheral circulatory blood of a living being, preferably of a mammal, and more preferably of a human being, said cell or tissue model comprising epithelial cells, preferably keratinocytes, or mesenchymatous cells, preferably dermal fibroblasts, or both epithelial cells and mesenchymatous cells, in order to obtain differentiation of CD14+ monocytes within the model into LCs, or IDCs, or into LCs and IDCs, by growing CD14+ monocytes in the presence of such epithelial cells or mesenchymatous cells or both.
- Advantageously, the growing of monocytes is carried out without adding any exogenous cytokine.
- Advantageously, the cell or tissue model is selected from the group consisting in an epidermis model, an epithelium model, a dermis model, a chorion model, a skin model or a model of a mucosa, in particular of a gingival or vaginal mucosa.
- Advantageously, the three-dimensional culture model comprises a dermal or chorion matrix support selected from the group consisting of:
-
- a collagen- or fibrin-based gel or film comprising mesenchymatous cells, in particular fibroblasts,
- a porous matrix which is made from collagen which may contain one or more glycosaminoglycans and/or optionally chitosan, these porous matrices either integrating mesenchymatous cells, in particular fibroblasts, or not,
- an inert support selected from the group consisting of a semi-permeable synthetic membrane, in particular a semi-permeable nitrocellulose membrane, a semi-permeable nylon membrane, a polytetrafluoroethylene (Teflon®, PTFE), a membrane or sponge, a semi-permeable polycarbonate or polyethylene terephthalate (PET) membrane, an inorganic membrane with a capillary porous structure of aluminum oxide (semi-permeable Anopore membrane), a semi-permeable polyester membrane, said inert support either containing mesenchymatous cells, in particular fibroblasts, or not.
- an inert support treated for polycarbonate- or polystyrene-based culture, said inert support either containing mesenchymatous cells, in particular fibroblasts, or not.
- Advantageously, the tissue model used comprises said dermal or chorion support on which epithelial cells, preferably keratinocytes, have been deposited at the surface.
- Advantageously, the cell or tissue model comprises at least one additional cell type, for example nerve cells and/or endothelial cells and/or melanocytes and/or lymphocytes and/or adipous cells and/or cutaneous annexes, such as bristles, hairs, sebaceous glands.
- Advantageously, a portion of the CD14+ monocytes differentiates into endothelial cells and macrophages, in particular when they are put into a cell or tissue model comprising at least mesenchymatous cells.
- Advantageously, the method mainly comprises LCs, or IDCs, or a mixture of LCs and IDCs, or a mixture of LCs, IDCs, endothelial cells and macrophages, or a mixture of IDCs, endothelial cells and macrophages.
- Advantageously, the cell or tissue model comprises an epithelial portion on a conjunctive matrix and is characterized in that the majority of the population of LCs are localized in the epithelial portion, and in that the majority of the IDCs, the macrophages and the endothelial cells are localized in the conjunctive matrix.
- The invention according to a third aspect, relates to a cell model comprising at least one of said LC and/or IDC populations, and further optionally comprising a population of macrophages and/or endothelial cells, capable of being obtained according to a method as defined earlier.
- Said model is characterized in that the obtained DCs are different from those obtained according to the methods described earlier, the main differences being concerned with synchronization of the cell differentiation steps for LCs and IDCs.
- The invention according to the fourth aspect, relates to a tissue model, comprising at least one of said LC and/or IDC populations, and further optionally comprising a population of macrophages and/or endothelial cells, capable of being obtained according to a method as defined earlier, said tissue model being selected from the group consisting of an epidermis model, an epithelium model, a dermis model, a chorion model, a skin model, or a model of a mucosa, in particular of a gingival or vaginal mucosa.
- Advantageously, the cell or tissue model described above is immunocompetent.
- Advantageously, the tissue model comprises an epithelial portion comprising epithelial cells, such as keratinocytes, and a conjunctive matrix comprising mesenchymatous cells, such as dermal or chorion fibroblasts, said model being characterized in that the LCs are essentially localized in the epithelial portion, and in that the present IDCs and macrophages and/or endothelial cells are essentially localized in the conjunctive matrix.
- Said model is characterized in that the obtained DCs are different from those obtained according methods described earlier, the main differences being concerned with the more homogenous cell distribution of LCs and DCCs in the present three-dimensional culture models.
- The invention according to a fifth aspect relates to frozen CD14+ monocytes, isolated from the peripheral circulatory blood of a living being, in particular of a human being.
- In particular with the invention, it is possible to generate populations of different DCs, the different functionalities of which may account for the whole of the phenomena involved in the organism's defense/infection processes, such as irritation, allergenicity and sensitization phenomena.
- Thus, the invention according to sixth aspect, relates to the use of at least one cell or tissue model as defined earlier as an investigation model in the field of cosmetics, dermo-pharmacy or pharmacy, and/or for active ingredient selection.
- Another interesting use of LCs and/or IDCs is the utilization for assessing the irritating versus the sensitizing potency of new molecules. European directive 2003/15/EC, which prohibits since 2005 the use of animals for assessing the toxicity of a cosmetic finished product, strongly urges public and industrial laboratories to develop in vitro or in silico predictive methods for predicting the sensitizing potency of new molecules. In this context, because of their key role, in triggering contact allergy, the use of cutaneous DCs as an alternative method to animal experimentation, is today an axis of development.
- The invention according to a seventh aspect relates to the use of at least one cell or tissue model as defined earlier, for investigating phenomena occurring in the organism's defense/infection processes, and activity, in particular the immuno-stimulating or immunosuppressive activity, of an active ingredient or for assessing or for inducing immunomodulation (immunotolerance or immunoactivation) by said active ingredient, or for conducting in vitro tests for predicting the allergizing/irritating/sensitizing potency of external agents or for investigating toxicity of molecules or chemicals.
- The invention according to an eighth aspect relates to the use of at least one cell or tissue model as defined earlier, for investigating the physiopathology of epithelial barriers; irritation of the skin and mucosae; aggressions of a biological nature such as for example viruses, retroviruses, such as HIV, bacteria, fungi, micro-organisms, particle antigens; phototoxicity; photoprotection; the effect of active ingredients, in particular of cosmetic or pharmaceutical ingredients; the effect of finished products, in particular of cosmetic or pharmaceutical products: the effect of molecules or chemicals; the mechanisms for infection by a pathogenic agent.
- Advantageously, this invention relates to investigating toxicity of active ingredients or other substances. Preferably this investigation is carried out by studying cell labels, for example those labels of DCs.
- The invention according to a ninth aspect relates to the use of at least one cell or tissue model as defined earlier, for investigating mechanisms involved in the phenomena of viral infection, replication and transmission of viruses, including retroviruses like HIV, or for investigating and developing alternative therapeutic methods, including the administration of vaccines or drugs.
- The invention according to a tenth aspect relates to the use of at least one cell or tissue model as defined earlier for detecting the presence of a pathogenic agent such as for example viruses, retroviruses, such as HIV, bacteria, fungi, micro-organisms, particle antigens.
- The invention according to an eleventh aspect relates to the use of at least one cell or tissue model as defined earlier, for a medical, biomedical, or cosmetic application, in particular for modulating the immune or tolerance response in vitro or in vivo, as a result of an environmental aggression, in particular of the physical type, such as UV irradiation, of the chemical type, such as irritating/allergizing/sensitizing agents, of the biological type, in particular with a preventive or curative therapeutic purpose.
- The invention according to a twelfth aspect relates to the use of at least one cell or tissue model as defined earlier, for cell or tissue engineering applications, for medical or biomedical applications, for example in anti-cancer cell therapy, for example by a DCs injection capable of stimulating the immune response; for example in cell therapy in the case of an auto-immune disease, for example by creating an immunotolerance stimulation, for example by producing anergic T cells; for example in gene therapy of diseases affecting the immunitary system; or for developing and making vaccines.
- The invention according to a thirteenth aspect relates to a method for making a tissue model comprising:
-
- isolation of CD14+ monocytes from peripheral circulatory blood of a living being,
- sowing skin or mucosal cells on a support and growing them in a nutritious medium in order to obtain reconstructed tissue,
- sowing in the reconstructed tissue CD14+ monocytes either simultaneously or not with skin or mucosal cells,
- growing the reconstructed tissue comprising CD14+ monocytes and skin or mucosal cells under conditions allowing differentiation of CD14+ monocytes into LCs, into a mixture of IDCs, endothelial cells and macrophages, into a mixture of LCs, IDCs, endothelial cells and macrophages, the skin cells being epidermal keratinocytes when the reconstructed tissue is an epidermis model, the skin cells being dermal fibroblasts when the reconstructed tissue is a dermis model, the mucosal cells being epithelial mucosal cells when the reconstructed tissue is an epithelium model, the mucosal cells being mucosal fibroblasts when the reconstructed tissue is a chorion model.
- The epithelial cells are for example isolated from at least one skin tissue.
- Sowing of the skin or mucosal cells may be carried out before sowing or after having sown CD14+ monocytes.
- Preferably, sowing of CD14+ monocytes is carried out simultaneously with the sowing of skin or mucosal cells.
- The invention according to a fourteenth aspect relates to a method for making a reconstructed skin or a reconstructed mucosa comprising an epithelial portion comprising keratinocytes or epithelial mucosal cells, optionally in the presence of Merkel cells and/or melanocytes, and a conjunctive matrix comprising dermal or mucosal fibroblasts, said method comprising:
-
- sowing and growing in a nutritious medium, keratinocytes or epithelial mucosal cells, possibly in the presence of Merkel cells and/or melanocytes, at the surface of a dermis or chorion model, comprising IDCs and optionally endothelial cells and macrophages, said dermis or chorion model being able to be obtained by a method for making a dermis or chorion model as defined above,
- sowing and growing either simultaneously with keratinocytes or epithelial mucosal cells or not, CD14+ monocytes isolated from peripheral circulatory blood of a living being in the presence of keratinocytes or epithelial mucosal cells under conditions allowing differentiation of CD14+ monocytes into LCs.
- Advantageously, the cells are cells of a human being. Preferably, these methods for making tissue models do not comprise any addition of exogenous cytokine.
- Other objects, features and advantages of the invention will become clearly apparent to one skilled in the art after reading the explanatory description which refers to examples which are only given as an illustration and which may by no means limit the scope of the invention.
- The examples are an integral part of the presence invention and any feature which appears to be novel relatively to any prior state of the art, from the description taken as a whole, including the examples, is an integral part of the invention in its function and in its generality.
- Thus, each example has a general scope.
- On the other hand, in the examples all the percentages are given by weight, unless stated otherwise, and the temperature is expressed in degrees Celsius, unless stated otherwise, and the pressure is atmospheric pressure, unless stated otherwise.
- Methods for Separating Monocytes from Peripheral Circulatory Blood
- The peripheral circulatory blood was harvested by sampling venous blood on one or more human donors, preferably in vacutainers or bags supplemented with usual anti-coagulant products such as lithium heparin.
- Separation of monocytes from circulatory blood may advantageously be performed according to the following protocols:
- 1. After centrifuging blood on a lymphocyte separation medium, the mononucleated cells are recovered, and then:
-
- Either labeled with a cocktail of antibodies, such as for example anti-CD3, anti-CD7, anti-CD16, anti-CD19, anti-CD56, anti-CD123 antibodies, anti-glycophorin A coupled with magnetic beads. After passing over a magnetized column, only the non-labeled monocytes are eluted and recovered,
- Or labeled with a specific antibody of the monocytes, such as an anti-CD14 antibody, coupled with magnetic beads; after passing over a magnetic column, only the labeled monocytes are retained in the column. After elution from the column, the labeled monocytes are recovered.
- Or labeled with a specific antibody of the monocytes, such as an anti-CD16 antibody, coupled with a fluorochrome, such as phycoerythrin. After cell sorting in flux cytometry, only the labeled monocytes are recovered.
- 2. The monocytes are recovered by proceeding with any physical separation method well-known to one skilled in the art and notably by sedimentation or centrifugation and they are eluted as such for subsequent cultures.
- 3. For 100 mL of sample blood, up to about 150 million (±20 million) mononucleated cells are extracted and up to 40 million monocytes are purified.
- Method for Freezing Monocytes Isolated from Peripheral Circulatory Blood
- The monocytes, obtained as described in Example 1, are suspended in a nutritious medium, for example RPMI medium, supplemented with serum and a cryoprotective agent, such as DMSO (dimethyl sulfoxide), and then frozen.
- When thawing out monocytes, cell mortality is less than 30%.
- For 100 mL of sample peripheral circulatory blood, up to 80.106 monocytes are frozen, and up to 76.106 monocytes are recovered after thawing them out.
- Monocytes were obtained according to the process of Example 1 or 2.
- 1 to 2.106 human keratinocytes and 1 to 2.106 human monocytes (obtained according to Example 1 or 2) are jointly grown in a nutritious medium, for example of the K-SFM type, in culture dishes, for example of the 6-well plate type. The joint culture is maintained for 6 days in a nutritious medium, for example of the K-SFM type, without adding any exogenous cytokine.
- The cells are then recovered by an enzymatic method well-known to one skilled in the art and notably by trypsination. 2.105 cells of the mixed cell suspension consisting of keratinocytes and monocytes are incubated with a monoclonal anti-Langerine antibody, and then analyzed in flux cytometry. We observe up to 40% of Langerine+ LCs.
- Monocytes were obtained according to the process of Example 1 or 2.
- 1 to 2.106 human fibroblasts and 1 to 2.106 human monocytes (obtained according to Example 1 or 2) are jointly grown in a nutritious medium, for example of the FBM type, in culture dishes for example of the 6-well plate type. The joint culture is maintained for 6 days in a nutritious medium, for example of the FBM type, without adding any exogenous cytokine.
- The cells are then recovered by an enzymatic method well-known to one skilled in the art and notably by trypsination. 2.105 cells of the mixed cell suspension consisting of fibroblasts and monocytes are incubated with a monoclonal anti-DC-SIGN antibody, and then analyzed in flux cytometry. We observe up to 60% of DC-SIGN+ DCCs.
- The use of Monolayer Pluricellular Models Described in Examples 3 and 4 for Investigating the Profile of Cytokines Secreted under the Effect of an Active Ingredient
- In order to assess the irritating, sensitizing, allergizing potency, and to estimate a possible pro- or anti-inflammatory activity of an active ingredient intended for human skin, we quantify in the culture supernatants, secretion of cytokines, for example, IL-1, IL-6, IL-8, IL-10, TNF-□ INF□, according to the following protocol:
- The model is made according to the protocol described in Example 3 or 4.
- Retinol is then added into the culture medium at a final concentration of 0.05% for 3 days.
- The culture supernatants are then recovered and analyzed.
- It is observed that retinol causes stimulation of secretion of pro-inflammatory cytokines.
- In order to assess the capacity of the LCs and DCCs of inducing immune and/or tolerogenic responses towards an active ingredient or not, we studied their phenotype profile by flux cytometry, according to the following protocol:
-
- The model is made according to the protocol described in Example 3 or 4.
- The active ingredient is then added into the culture medium at various concentrations and for 3 days.
- The cells are then recovered by trypsination. 2.105 cells of the mixed cell suspension consisting of keratinocytes and LCs or of fibroblasts and DCCs are incubated in an antibody battery: anti-CCR7, anti-HLA-DR, anti-CD80, anti-CD83, anti-CD86, anti-DC-LAMP.
- With cell phenotyping, the immunoactivating (induction and/or increase of the expression of labeled molecules) or immunosuppressive profile (inhibition and/or suppression of the expression of labeled molecules) of the tested active ingredients may be established.
- The immunomodulating effect of an active ingredient after an irritating, sensitizing or allergizing stress is investigated according to the following protocol:
-
- The model is made according to the protocol described in Example 3 or 4.
- 300 μl of TNP (2,4,6-trinitrobenzene-sulfonic acid) are then added at a concentration of 5 mM for 30 min at 37° C.
- After this stimulation, the active ingredients tested at various concentrations are added into the culture medium for 2 days.
- The culture media comprising the cells are then recovered in order to investigate the secretion of immune cytokines, for example IL-12; the cells are recovered and then incubated either with an anti-Langerine antibody or with an anti-DC-SIGN antibody in order to sort the LCs or the DCCs in flux cytometry, respectively.
- The sorted LCs or DCCs are then sown in migration chambers of the Boyden type (porosity of the membrane from 5 to 8 μm either covered with MATRIGEL™ or not) and then incubated for up to 72 hrs at 37° C.
- The number of LCs or DCCs having migrated is quantified, for example by counting in optical microscopy.
The results of migration and/or IL-12 synthesis and secretion tests enable the immunomodulating profile of the active ingredients tested to be established.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the following protocol:
-
- 0.5 to 1.106 keratinocytes of normal human skin were sown in inserts of the Boyden chamber type (membrane with porosity 0.4 μm) and then grown in a nutritious medium of the DMEM-Glutamax type supplemented with calf serum, ascorbic acid and preferably a final concentration of 1 mM of EGF (epidermal growth factor) and preferably at a final concentration of 10 ng/mL, hydrocortisone and preferably at a final concentration of 0.4 μg/mL, umulin and preferably at a final concentration of 0.12 IU/mL, isuprel and preferably at a final concentration of 0.4 μg/mL, triiodothyronine and preferably at a final concentration of 2.10−9 M, adenine and preferably at a final concentration of 24.3 μg/mL, normocin and preferably at a final concentration of 100 μg/mL, for 2 days.
- Next 1 to 5.104 monocytes were sown at the surface of the epithelium equivalent, which was grown for a further period of 2 days.
- The cultures were then placed at the air-liquid interface for a further period of 10 days in the same medium used for the immersion culture, except for calf serum, hydrocortisone, umulin, isuprel and triiodothyronine.
- The cultures were then embedded in an amorphous resin, such as Tissue-Teck®, and directly frozen in liquid nitrogen.
- Immunohistochemical investigations were then conducted on histological sections in order to characterize the cell types by means of specific antibodies.
- The performed labelings showed the presence of LCs (Langerine+ cells).
- Thus, the monocytes integrated into the reconstructed epidermis model differentiated into DCs of the LC type as demonstrated by observation of the lectin, Langerine.
- Three-Dimensional Pluricellular Pigmented and/or Nervous Reconstructed Epidermis Model Containing LCs
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the protocol described in Example 8, by simultaneously sowing together 0.5 à 1.105 melanocytes and/or Merkel cells stemming from normal human skin with keratinocytes.
- In addition to the labelings described in Example 8, labeling of the melanocytes (HMB45) and a DOPA reaction was carried out in order to detect melanin as well as labeling with an anti-keratin 20 antibody for identifying Merkel cells. Thus, the monocytes integrated into the pigmented and/or nervous reconstructed epidermis model differentiated into DCs of the LC type as demonstrated by observation of the lectin, Langerine.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the protocol described in Example 8 with the following changes:
-
- Normal human keratinocytes were replaced with epithelial cells of normal human gingival and vaginal mucosae.
- The percentage of serum in the culture medium was 1%.
- Growing was totally performed with immersion in the medium.
- The achieved labelings show the presence of LCs (Langerine+ cells).
- Thus, the monocytes integrated into the epithelium model of gingival and vaginal reconstructed mucosae differentiated into DCs or the LC type as demonstrated by observation of the lectin Langerine.
- This model is the association of a reconstructed dermis culture on which an additional culture of a reconstructed epidermis is performed.
- The reconstructed dermis model was made according to the following protocol:
-
- 0.5 to 1.106 fibroblasts of normal human skin was sown on a matrix substrate based on cross-linked collagen with diphenyl-phosphoryl azide, and then grown in a nutritious medium, DMEM-Glutamax supplemented with 10% calf serum, ascorbic acid and preferably at a final concentration of 1 mM, EGF (epidermal growth factor) and preferably at a final concentration of 10 ng/mL, normocin and preferably at a final concentration of 100 μg/mL, for 14 days.
- The reconstructed skin model was made according to the following protocol:
-
- 0.5 to 1.106 normal human keratinocytes were sown on the dermal equivalent, and then grown in a nutritious medium, DMEM-Glutamax/Ham F-12 (ratio 3/1 v/v) supplemented with calf serum, ascorbic acid and preferably at a final concentration of 1 mM, EGF (epidermal growth factor) and preferably at a final concentration of 10 ng/mL, hydrocortisone and preferably at a final concentration of 0.4 μg/mL, umulin and preferably at a final concentration of 0.12 IU/mL, isuprel and preferably at a final concentration of 0.4 μg/mL, triiodothyronine and preferably at a final concentration of 2.10−9 M, adenine and preferably at a final concentration of 24.3 μg/mL, normocin and preferably at a final concentration of 100 μg/mL. The growing continued for 7 days in the immersed condition.
The cultures were then placed at the air-liquid interface for 14 additional days in the same medium as the immersion culture, except for calf serum, hydrocortisone, isuprel, triiodothyronine and umulin. Thus, in vitro reconstruction of both cell compartments of the skin, the epidermis and the dermis, was obtained.
- 0.5 to 1.106 normal human keratinocytes were sown on the dermal equivalent, and then grown in a nutritious medium, DMEM-Glutamax/Ham F-12 (ratio 3/1 v/v) supplemented with calf serum, ascorbic acid and preferably at a final concentration of 1 mM, EGF (epidermal growth factor) and preferably at a final concentration of 10 ng/mL, hydrocortisone and preferably at a final concentration of 0.4 μg/mL, umulin and preferably at a final concentration of 0.12 IU/mL, isuprel and preferably at a final concentration of 0.4 μg/mL, triiodothyronine and preferably at a final concentration of 2.10−9 M, adenine and preferably at a final concentration of 24.3 μg/mL, normocin and preferably at a final concentration of 100 μg/mL. The growing continued for 7 days in the immersed condition.
- Monocytes were obtained according to the process of Example 1 or 2.
- Growing the reconstructed dermis was performed according to Example 11.
- The model is made according to the following protocol:
-
- 1 to 5.104 monocytes were sown at the surface of the dermal equivalent, which was grown for a further period of 7 days,
- The cultures were then embedded in an amorphous resin, such as Tissue-Teck®, and then directly frozen in liquid nitrogen.
- Immunohistochemical investigations were carried out on histological sections in order to characterize the cell types present by means of specific antibodies.
- The performed labelings showed the simultaneous presence of DDC (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells).
- Thus, the monocytes integrated and then grown in our reconstructed dermis model are capable of simultaneously differentiating into DCs of the DDC type, into macrophages and endothelial cells.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the protocol described in Example 12 with the following changes:
-
- The fibroblasts were fibroblasts stemming from normal human gingival and vaginal mucosae.
- The performed labelings showed the simultaneous presence of IDCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells).
- Thus, the monocytes integrated and then grown in our reconstructed chorion model of the gingival and vaginal type are capable of simultaneously differentiating into DCs of the IDC type, into macrophages and endothelial cells.
- Monocytes were obtained according to the process of Example 1 or 2.
- The culture of the reconstructed skin model was performed according to Example 11.
- The model was made according to the following protocol:
-
- 1 to 5.104 monocytes were jointly sown with keratinocytes on the dermal equivalent.
- The performed labelings show the presence of LCs (Langerine+ cells and Birbeck+ granules) in the epidermal compartment of the cultures.
- Thus, the monocytes grown with keratinocytes in our reconstructed skin model differentiate into DCs of the LC type.
- Three-Dimensional Pluricellular Pigmented and/or Nervous Reconstructed Skin Model Containing LCs
- Monocytes were obtained according to the process of Example 1 or 2.
- Growth of the reconstructed skin model containing LCs was performed according to Example 14.
- The model was made according to the following protocol:
-
- 1 to 5.104 melanocytes and/or Merkel cells stemming from normal human skin were jointly sown with keratinocytes and monocytes on the reconstructed dermis.
- In addition to the labelings described in Example 14, labeling of the melanocytes (HMB45) and a DOPA reaction was carried out in order to detect melanin, as well as labeling with an anti-keratin 20 antibody for identifying Merkel cells.
- The labeling demonstrated that the monocytes grown with keratinocytes, melanocytes and/or Merkel cells in our reconstructed skin model differentiate into DCs of the LC type.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the protocol described in Example 14 with the following changes:
-
- Keratinocytes were replaced with epithelial cells of normal human gingival and vaginal mucosae, and the fibroblasts are fibroblasts stemming from normal human gingival and vaginal mucosae.
- The percentage of calf serum in the culture medium for the epithelialization step was 1%.
- Growth was totally accomplished in immersion in the medium
- The performed labelings showed the presence of LCs (Langerine+ cells and Birbeck+ granules) in the epithelial compartment of the cultures. Thus, the monocytes grown with epithelial cells of the gingival or vaginal type in our reconstructed mucosa model differentiate into DCs of the LC type.
- Monocytes were obtained according to the process of Example 1 or 2.
- Growth of the reconstructed skin model was achieved according to Example 11.
- The model was made according to the following protocol:
-
- 1 to 5.104 monocytes were sown at the surface of the dermal equivalent which was grown for a further period of 7 days.
- The performed labelings showed the simultaneous presence of DCCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells). Thus, the monocytes integrated into the dermal compartment of the reconstructed skin model and grown therein differentiate into DCs of the DDC type, into macrophages and endothelial cells, simultaneously.
- Three-Dimensional Pluricellular Pigmented and/or Nervous Reconstructed Skin Model Containing DCCs, Macrophages and Endothelial Cells
- The model was made according to the protocol described in Example 17, by simultaneously sowing together 1 to 5.104 melanocytes and/or Merkel cells stemming from normal human skin with keratinocytes.
- In addition to the labelings described in Example 17, labeling of melanocytes (HMB45) and a DOPA reaction was carried out in order to detect melanin, as well as a labeling with anti-keratin 20 antibody for observing Merkel cells. The labeling demonstrated that the monocytes integrated into the dermal compartment of the pigmented and/or nervous reconstructed skin model and grown therein differentiate into DCs of the DDC type, into macrophages and endothelial cells simultaneously.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the protocol described in Example 17 with the following changes:
-
- The keratinocytes were replaced with epithelial cells of normal human gingival and vaginal mucosae, and the fibroblasts are fibroblasts stemming from normal human gingival and vaginal mucosae.
- The percentage of calf serum in the culture medium for the epithelialization step was 1%.
- Growth was totally performed in immersion in the medium.
- The performed labelings showed the simultaneous presence of IDCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ cells and CD36+ ). The monocytes integrated into the conjunctive compartment of the reconstructed mucosa model of the gingival and vaginal type and grown therein differentiate into DCs of the IDC type, into macrophages and into endothelial cells, simultaneously.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the following protocol:
-
- The reconstructed dermis model containing DCCs, macrophages and endothelial cells was made according to Example 12.
- The reconstructed skin model containing LCs was made according to Example 14.
- The performed labelings showed the simultaneous presence of LCs (Langerine+ cells and Birbeck+ granules) in the epidermal compartment of the cultures, and of DCCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells) in the dermal compartment of the cultures. Thus, the monocytes successively grown in the dermal compartment and then with keratinocytes in the reconstructed skin model differentiate into DCs of the LC type in the epidermal compartment and into DCs of the DDC type, into macrophages and endothelial cells, in the dermal compartment, simultaneously.
- Three-Dimensional Pluricellular Pigmented and/or Nervous Reconstructed Skin Model Containing LCs, DCCs, Macrophages and Endothelial Cells
- Monocytes were obtained according to the process of Example 1 or 2.
- The model is made according to the following protocol:
-
- The reconstructed dermis model containing DCCs, macrophages and endothelial cells is made according to Example 12.
- The pigmented and/or nervous reconstructed skin model containing LC1s is made according to Example 15.
- The performed labelings detect simultaneous presence of LCs (Langerine+ cells and Birbeck granules) in the epidermal compartment of the cultures, and of DCCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells) in the dermal compartment of the cultures. Thus, the monocytes successively grown in the dermal compartment and then simultaneously with keratinocytes, melanocytes and/or Merkel cells in the pigmented and/or nervous reconstructed skin model differentiate into DCs of the LC type in the epidermal compartment and into DCs of the DDC type, into macrophages and into endothelial cells in the dermal compartment simultaneously.
- Monocytes were obtained according to the process of Example 1 or 2.
- The model was made according to the following protocol:
-
- The reconstructed chorion model containing IDCs, macrophages and endothelial cells was made according to Example 13.
- The reconstructed mucosa model containing LCs was made according to Example 16.
- The performed labelings showed the simultaneous presence of LCs (Langerine+ cells and Birbeck+ granules) in the epithelial compartment, and the presence of IDCs (DC-SIGN+ cells), macrophages (CD68+ cells) and endothelial cells (CD31+ and CD36+ cells) in the conjunctive compartment of the cultures. Thus, the monocytes successively cultivated in the conjunctive compartment and then with epithelial cells in the reconstructed mucosa model of the gingival of vaginal type differentiate into DCs of the LC type in the epithelial compartment and into DCs of the IDC type, into macrophages and endothelial cells in the conjunctive compartment simultaneously.
- In order to investigate the influence of various environmental factors and in particular of solar UV radiation, the migration and the phenotype profile of LCs and DCCs was assessed in the reconstructed skin model by immuno-histochemical investigations, according to the following protocol:
-
- Models were made according to protocol described in Example 20
- On the 42nd day of culture, the reconstructed skins were irradiated at a single dose of 526 kJ/cm2 of solar energy corresponding to 2 J/cm2 of UVA and 0.5 J/cm2 of UVB (solar irradiator Suntest CPS+, ATLAS). Growth continued for a further period of 2 days.
- The immuno-histochemical investigations were then made with an antibody battery (anti-CD1a, anti-CD80, anti-CD83, anti-CD86, anti-CCR7, anti-DC-LAMP, anti-DC-SIGN, anti-Langerine, anti-HLA-DR) in order to observe migration of the LCs and DCCs and to characterize their phenotype condition.
After solar UV irradiation, migration of the LCs was observed in the dermal compartment of the cultures, as well as acquisition of the expression of the CCR7 receptor on the Cls and DCCs. Further, only the LCs which have migrated into the dermal compartment, expressed the maturation label DC-LAMP. The pluricellular model of the present invention is therefore predictive of UV stress by the targeting of LCs and DCCs which have migration, activation and maturation capability.
- In order to assess the anti-inflammatory potency of active ingredients intended for human skin, the secretion of pro-inflammatory cytokines, for example IL-1, IL-6, IL-8, TNF-alpha and INF-gamma, was quantified in the culture supernatants according to the following protocol:
-
- Models were made according to the protocol described in Example 20.
- On the 42nd day of culture, the reconstructed skins were irradiated with a unique dose of 526 kJ/cm2 of solar energy corresponding to 2 J/cm2 of UVA and 0.5 J/cm2 of UVB (solar irradiator Suntest CPS+, ATLAS).
- Subsequently, 8 μl of a cosmetic formulation which contained either 3% anti-oxidant active for example Flavagrum® (Hesperitine Laurate, ENGELHARD) and Flavenger® (Quercitine Caprylate, ENGELHARD) or not, were applied on the reconstructed skins for 10 days.
- At the end of the treatment, the reconstructed skins were grown for a further period of 48 hours in the immersion medium and then the efficiency of the anti-oxidant treatment was assessed by: (1) analysis of cell viability (methylthiazoletetrazolium—MTT test), (2) flux cytometry dosage (CBA—Cytometric Bead Array) of the secretion of cytokines in the culture supernatants. This analysis is shown in the table below:
-
Reconstructed skin Reconstructed skin Reconstructed skin Reconstructed ski UV irradiated + UV irradiated + Control UV irradiated Flavagrum Flavenge MTT (viability 100% 76% 88% 92% IL1β (pg/mL) 76 179 125 97 IL6 (pg/mL) 379 649 452 426 IL8 (pg/mL) 275 395 312 294 TNFβ (pg/mL 53 152 105 89 indicates data missing or illegible when filed
With the inventive methods, it is possible to see that solar UV stress induces a reduction in the cell viability as well as an increase in the synthesis of pro-inflammatory interleukins. It is therefore of interest to limit this synthesis of pro-inflammatory molecules as well as cell mortality by using properly selected active ingredients. Among the screened active ingredients, two of them, Flavagrum and Flavenger, have demonstrated efficiency with a possible tendency to restore the reference level for both of these parameters. - In order to assess whether LCs and/or DCCs are capable of inducing immune and/or tolerogenic responses towards an active ingredient or not, the functionality of the cells to stimulate proliferation of allogenic naive T lymphocytes was investigated according to the following protocol:
-
- Models were made according to the protocol described in Examples 14, 17 and 20.
- On the 42nd day of culture, either the active ingredient was directly applied on the reconstructed skins by means of a swab (topical application) or the active ingredient was introduced into the culture medium (systemic application) for 10 days.
- At the end of the treatment, the cultures were successively digested by 2 hr enzymatic treatments at 37° C. with trypsin (1 mg/mL) and with collagenase (1 mg/mL) in order to recover the LCs and/or DCCs.
- The LCs and/or DCCs were grown for 3 days with allogenic naive T lymphocytes in an RPMI culture medium supplemented with 10% human AB serum. A range of LCs and/or DCs between 125 and 8,000 cells was achieved and grown with 105 naive T lymphocytes. On the 3rd day of the mixed lymphocyte culture, 20 μl of 5 mCi tritiated thymidine was added for a period of 18 hrs.
- The results are expressed in the table below with the number of LCs and/or DCCs in abscissae and in ordinates the incorporation of tritiated thymidine into allogenic naive T lymphocytes expressed in cpm (counts per minute):
-
Number of LCs or DCCs CPM (untreated) CPM (active) 125 500 500 250 800 1500 500 1000 10000 1000 1500 22500 2000 2300 39850 4000 2800 47250 6000 3000 52500 8000 3800 55000
After treatment with our active X, the LCs and/or DCCs strongly stimulated proliferation of T lymphocytes (between 5.104 and 7.104 cpm) as compared with the untreated LCs and/or DCCs which only induce weak proliferation of naive T lymphocytes (between 1.103 and 4.103 cpm). - The immunomodulating effect of an active ingredient after inducing an irritating, sensitizing and allergizing stress was investigated according to the following protocol:
-
- The model was made according to the protocol described in Example 12.
- After 21 days of culture, the irritant (sodium dodecyl sulphate) at the final concentration of 2% and the sensitizer DNCB (1,4-chloro-dinitrobenzene) at a final concentration of 0.25% were introduced into the culture medium for 24 hrs.
- Next, 100 μl of a cosmetic formulation either containing a soothing active at the final concentration of 3% or not, was introduced into the culture medium of equivalent dermises for 3 days.
- At the end of the treatment, the culture supernatants were recovered for dosing IL-10 and IL-12 for example, and an immunohistochemical study was developed with an antibody battery: anti-CD80, anti-CD83, anti-CD86, anti-CCR7, anti-DC-LAMP, anti-HLA-DR.
- With the results of the IL-10 and IL-12 secretion and of the phenotype study of the DCCs by immunohistochemistry, the immunomodulating profile of the tested active ingredients was established. Thus, our pluricellular model is therefore a predictive tool with which it is possible to assess the potential immmunomodulating effect of an active ingredient by screening DCCs which have cytokine secretion, activation and maturation capabilities.
- While the invention has been described in terms of various preferred embodiments, those skilled in the art will recognize that various modifications, substitutions, omissions and other changes may be made without departing from the spirit of the present invention.
Claims (31)
1. A method for preparing Langerhans cells or interstitial dendritic cells, or both Langerhans cells and interstitial dendritic cells from CD14+ monocytes, said method comprising
obtaining CD14+ monocytes from peripheral circulatory blood of a mammal; and
placing the monocytes into a cell culture environment comprising epithelial cells or mesenchymatous cells, or both epithelial cells and mesenchymatous cells, but wherein there has been no addition of exogenous cytokine into the cell culture environment.
2. A method for growing CD14+ monocytes which differentiate into Langerhans cells, interstitial dendritic cells, or both Langerhans cells and interstitial dendritic cells, the growing method comprising the integration in a cell or tissue model of CD 14+ monocytes obtained from peripheral circulatory blood of a living mammal, wherein said cell or tissue model comprises epithelial cells or mesenchymatous cells, or both epithelial cells and mesenchymatous cells.
3. The method according to claim 2 wherein no exogenous cytokine is added to the growth medium.
4. The method according to claim 2 wherein the cell or tissue model is selected from the group consisting of an epidermis model, an epithelium model, a dermis model, a chorion model, a skin model, and a mucosa model.
5. The method according to claim 2 wherein the cell or tissue culture model comprises a dermal or chorion matrix support selected from the group consisting of:
a collagen- or fibrin-based gel or film comprising mesenchymatous cells;
a collagen based porous matrix comprising chitosan or at least one glycosaminoglycan, or both chitosan and at least one glycoaminoglycan;
an untreated inert support selected from the group consisting of a semi-permeable synthetic membrane, in particular a semi-permeable nitrocellulose membrane, a semi-permeable nylon membrane, a polytetrafluoroethylene membrane or sponge, a semi-permeable polycarbonate or polyethylene terephthalate membrane, an inorganic membrane with a capillary porous structure of aluminum oxide, cellulose acetate or ester, a semi-permeable hydrophilized polytetrafluoroethylene, a semi-permeable polyester membrane; and an inert support treated for polycarbonate- or polystyrene-based culture.
6. The method according to claim 5 wherein the matrix support is either the collagen based porous matrix, the untreated inert support, or the treated support, and wherein mesenchymatous cells are integrated into the matrix support.
7. The method according to claim 6 wherein the mesenchymatous cells are fibroblasts.
8. The method according to claim 5 wherein epithelial cells are placed at the surface of the dermal or chorion matrix support.
9. The method according to claim 8 wherein the epithelial cells are keratinocytes.
10. The method according to claim 2 wherein the cell or tissue model comprises at least one additional cell type selected from the group consisting of nerve cells, Merkel cells, endothelial cells, macrophages, melanocytes, lymphocytes, adipous cells, or cutaneous annexes.
11. The method according to claim 6 wherein a portion of the monocytes differentiate into endothelial cells or macrophages or both endothelial cells and macrophages.
12. The method according to claim 5 wherein the cell or tissue model comprises an epithelial portion and a conjunctive matrix, and wherein the majority of Langerhans cells are localized in the epithelial portion and the majority of interstitial/dermal cells, macrophages and endothelial cells are localized in the conjunctive matrix.
13. A method for differentiating CD14+ monocytes into Langerhans cells or interstitial dendritic cells, or both Langerhans cells and interstitial dendritic cells comprising the following steps:
obtaining CD14+ monocytes from the circulatory blood of a mammal;
maintaining the monocytes under conditions which do not promote their differentiation into dendritic cells;
placing the monocytes into contact in a cell culture environment comprising epithelial cells or mesenchymatous cells, or both epithelial cells and mesenchymatous cells, under culture conditions promoting differentiation of the CD14+ monocytes into Langerhans cells or interstitial dendritic cells or both.
14. A cell model comprising a population of Langerhans cells or interstitial dendritic cells, or both Langerhans cells and interstitial/dermal dendritic cells, wherein said Langerhans cell and interstitial dendritic cell populations are obtained according to the method of claim 1 .
15. The cell model of claim 14 wherein said cell model further comprises a population of macrophages or endothelial cells.
16. A tissue model comprising a population of Langerhans cells or interstitial/dermal dendritic cells, or both Langerhans cells and interstitial dendritic cells, wherein said Langerhans cell and interstitial dendritic cell populations are obtained according to the method of claim 1 , and wherein said tissue model is selected from the group consisting of an epidermis model, an epithelium model, a dermis model, a chorion model, a skin model, and a mucosa model.
17. The tissue model according to claim 16 wherein said tissue model further comprises a population of macrophages or endothelial cells.
18. The tissue model according to claim 17 , characterized in that it comprises an epithelial portion comprising epithelial cells and a conjunctive matrix comprising mesenchymatous cells, and wherein the majority of Langerhans cells are localized in the epithelial portion and the majority of interstitial/dermal dendric cells are localized in the conjunctive matrix.
19. Frozen CD14+ monocytes, isolated from peripheral circulatory blood of a living being, in particular of a human being.
20. A method of storing CD14+ monocytes comprising:
obtaining CD14+ monocytes from the peripheral circulatory blood of a mammal;
suspending the monocytes in a medium comprising a cryoprotective agent; and
freezing the monocytes;
wherein the between the step of obtaining the monocytes and suspending the monocytes in the medium, the monocytes are maintained under conditions which do not promote their differentiation into dendritic cells.
20. The use of the cell model according to claim 14 as a research model in the field of cosmetics, dermo-pharmacy or pharmacy.
21. The use of the cell model according to claim 20 for one of the research areas selected from the group consisting of investigating the immune response to an external agent, investigating the immunostimulating or immunosuppressive potential of an active ingredient, toxicity investigation of active ingredients or other substances, investigating physiopathology of epithelial barriers, investigation of cosmetic or pharmaceutical product efficacy, and investigating the mechanisms for infection by a pathogenic agent.
22. The use of the tissue model according to claim 16 as a research model in the field of cosmetics, dermo-pharmacy, or pharmacy.
23. The use of the tissue model according to claim 22 for one of the research areas selected from the group consisting of investigating the immune response to an external agent, investigating the immunostimulating or immunosuppressive potential of an active ingredient, toxicity investigation of active ingredients or other substances, investigating physiopathology of epithelial barriers, investigation of cosmetic or pharmaceutical product efficacy, and investigating the mechanisms for infection by a pathogenic agent.
24. A method for making a tissue model comprising:
isolating CD14+ monocytes from peripheral circulatory blood of a living mammal,
sowing skin or mucosal cells of a mammal on a support and growing said skin or mucosal cells in a nutritious medium to obtain a reconstructed tissue,
sowing in said reconstructed tissue, CD14+ monocytes either simultaneously with said skin or mucosal cells or separately from said skin or mucosal cells,
growing the reconstructed tissue comprising the CD14+ monocytes and the skin or mucosal cells under conditions allowing differentiation of the CD14+ monocytes into Langerhans cells, into a mixture of institial dendritic cells, endothelial cells and/or macrophages, into a mixture of Langerhans cells, interstitial dendritic cells, endothelial cells, and/or macrophages.
25. The method of claim 24 where the tissue model is selected from the group consisting of an epidermis model, a dermis model, an epithelium model, and a chorion model.
26. A method according to claim 25 wherein
the skin cells are epidermal keratinocytes when the reconstructed tissue is an epidermis model;
the skin cells are dermal fibroblasts when the reconstructed tissue is a dermis model;
the mucosal cells are epithelial mucosal cells when the reconstructed tissue is an epithelium model;
and the mucosal cells being mucosal fibroblasts when the reconstructed tissue is a chorion model.
27. A method for making a reconstructed skin or a reconstructed mucosa comprising an epithelial portion comprising keratinocytes or epithelial mucosal cells and a conjunctive matrix comprising dermis or chorion fibroblasts, said method comprising:
sowing and growing in a nutritious medium, keratinocytes or epithelial mucosal cells, at the surface of a dermis or chorion model according to claim 24 ;
sowing and growing, either simultaneously or not, with keratinocytes or epithelial mucosal cells, CD14+ monocytes isolated from peripheral circulatory blood of a living being in the presence of the keratinocyes or epithelial mucosal cells under conditions allowing differentiation of CD14+ monocytes into LCs.
28. A method of differentiating CD14+ monocytes into immature and functional Langerhans cells comprising
obtaining CD14+ monocytes from peripheral circulatory blood of a mammal; and
placing the monocytes into a cell culture environment comprising keratinocytes but does not contain exogenous cytokines.
29. A method of differentiating CD14+ monocytes into immature and functional interstitial cells comprising
obtaining CD14+ monocytes from peripheral circulatory blood of a mammal; and
placing the monocytes into a cell culture environment comprising dermal fibroblasts.
28. A method of differentiating CD14+ monocytes into typical Langerhans cells and interstitial dendritic cells comprising
obtaining CD14+ monocytes from peripheral circulatory blood of a mammal; and
placing the monocytes into a cell culture environment comprising keratinocytes and dermal fibroblasts, but does not contain exogenous cytokines.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/897,617 US20090081783A1 (en) | 2007-09-01 | 2007-09-01 | Method for producing langerhans cells or interstitial dendritic cells or both from CD14+ monocytes |
US12/851,592 US20100297765A1 (en) | 2006-09-04 | 2010-08-06 | Method for producing langerhans cells or interstitial dendritic cells or both from cd14+ monocytes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/897,617 US20090081783A1 (en) | 2007-09-01 | 2007-09-01 | Method for producing langerhans cells or interstitial dendritic cells or both from CD14+ monocytes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/851,592 Continuation US20100297765A1 (en) | 2006-09-04 | 2010-08-06 | Method for producing langerhans cells or interstitial dendritic cells or both from cd14+ monocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090081783A1 true US20090081783A1 (en) | 2009-03-26 |
Family
ID=40472085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/897,617 Abandoned US20090081783A1 (en) | 2006-09-04 | 2007-09-01 | Method for producing langerhans cells or interstitial dendritic cells or both from CD14+ monocytes |
US12/851,592 Abandoned US20100297765A1 (en) | 2006-09-04 | 2010-08-06 | Method for producing langerhans cells or interstitial dendritic cells or both from cd14+ monocytes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/851,592 Abandoned US20100297765A1 (en) | 2006-09-04 | 2010-08-06 | Method for producing langerhans cells or interstitial dendritic cells or both from cd14+ monocytes |
Country Status (1)
Country | Link |
---|---|
US (2) | US20090081783A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11324787B2 (en) | 2017-01-05 | 2022-05-10 | Senzagen Ab | Analytical methods and arrays for use in the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201303485D0 (en) | 2013-02-27 | 2013-04-10 | Alcyomics Ltd | Skin model |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2743817B1 (en) * | 1996-01-23 | 1998-03-13 | Oreal | SKIN EQUIVALENT COMPRISING LANGERHAN CELLS |
-
2007
- 2007-09-01 US US11/897,617 patent/US20090081783A1/en not_active Abandoned
-
2010
- 2010-08-06 US US12/851,592 patent/US20100297765A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11324787B2 (en) | 2017-01-05 | 2022-05-10 | Senzagen Ab | Analytical methods and arrays for use in the same |
Also Published As
Publication number | Publication date |
---|---|
US20100297765A1 (en) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5101559B2 (en) | Generation of dendritic cells from CD14 positive monocytes in vitro | |
Seneschal et al. | Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells | |
EP1311658B1 (en) | Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells | |
JP2813467B2 (en) | Cell culture methods and media | |
Regnier et al. | Reconstructed human epidermis composed of keratinocytes, melanocytes and Langerhans cells | |
Gerlini et al. | Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells | |
KR101344201B1 (en) | Cosmetic Composition containing Immunocytes activation media for Anti-aging | |
McKeever et al. | Bovine afferent lymph veiled cells differ from blood monocytes in phenotype and accessory function. | |
WO2008028882A1 (en) | A method for producing langerhans cells and/or dermal/interstitial dentritic cells from cd14+ monocytes | |
Eljaafari et al. | Generation of stable monocyte-derived dendritic cells in the presence of high concentrations of homologous or autologous serum: influence of extra-cellular pH | |
EP1419240B1 (en) | Production and use of human cd124 and cd116 positive tumour cell lines in the production of allogenic or semi-allogenic immunotherapy agents | |
US20100297765A1 (en) | Method for producing langerhans cells or interstitial dendritic cells or both from cd14+ monocytes | |
CN116004538A (en) | Nanometer vesicle carrying dsRNA generated in cells, preparation and application | |
de Lastic et al. | Effect of dendritic cell state and antigen-presentation conditions on resulting T-cell phenotypes and Th cytokine profiles | |
Mizumoto et al. | Enhanced contact hypersensitivity in human monocyte chemoattractant protein-1 transgenic mouse | |
DE60130206T2 (en) | COMPOSITIONS AND METHODS OF PREPARING ANTIGEN-PRESENTING CELLS | |
Ayala-García et al. | Participation of epidermal langerhans cells in human pathology and their potential as targets for drug development: a review of literature | |
WO2007031273A2 (en) | Artificial immune-reconstituted epidermis equivalents | |
Steinman | Dendritic cells: clinical aspects | |
US20050064588A1 (en) | Epidermal melanocyte culture formulations | |
US20040152191A1 (en) | Process for the maturation of dendritic cells and for the activation of macrophages with RU 41740 | |
Kočiková et al. | Murine Langerhans cells cultured under serum-free conditions mature into potent stimulators of primary immune responses in vitro and in vivo | |
DE102004061289A1 (en) | Test kit for in vitro studies of effector action, e.g. for testing toxicity and/or allergenicity of topical agents, comprises test cells, cultured in vitro or recovered ex vivo, and immune cells | |
Silvano et al. | Differentiation of Human Hematopoietic Progenitor Cells Into Dendritic Cells In Vitro Under Stimulation of PPAR-Gamma | |
Stössel et al. | Maturation and Migration of Murine Dendritic Cells in Situ: Observations in a Skin Organ Culture Model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BASF BEAUTY CARE SOLUTIONS FRANCE SAS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BECHETOILLE, NICOLAS;ANDRE, VALERIE;ORLY, ISABELLE;AND OTHERS;REEL/FRAME:022212/0617;SIGNING DATES FROM 20081010 TO 20081117 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |